Neurocrine Biosciences | NBIX

Neurocrine Biosciences traded at $96.15 this Thursday March 23rd, increasing $1.00 or 1.05 percent since the previous trading session. Looking back, over the last four weeks, Neurocrine Biosciences gained 5.61 percent. Over the last 12 months, its price rose by 3.72 percent. Looking ahead, we forecast Neurocrine Biosciences to be priced at 91.25 by the end of this quarter and at 82.82 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
96.15
Daily Change
1.05%
Yearly
3.72%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
AbbVie 156.22 2.55 1.66% -2.53%
Acadia Pharmaceuticals 18.67 0.17 0.92% -31.23%
Acorda Therapeutics 0.60 0.01 0.84% -65.91%
Agios Pharmaceuticals 22.17 0.38 1.74% -25.50%
ALKERMES 25.89 0.06 0.23% -0.77%
Alnylam Pharmaceuticals 194.44 4.70 2.48% 18.78%
Amgen 233.68 3.85 1.68% -1.35%
Aptinyx Inc 0.14 -0.002 -1.19% -94.85%
Biogen 265.26 4.04 1.55% 24.53%
BioMarin Pharmaceutical 91.27 1.19 1.32% 12.84%
Cytokinetics 34.27 -0.10 -0.29% -9.03%
Dynavax Technologies 9.81 0.19 1.98% -13.95%
Enanta Pharmaceuticals 39.92 0.23 0.58% -41.09%
Exelixis 18.38 0.07 0.38% -14.63%
Gilead Sciences 78.78 0.97 1.25% 33.21%
Halozyme Therapeutics 33.53 0.67 2.04% -13.40%
Intercept Pharmaceuticals 13.78 0.19 1.40% -20.30%
Incyte Corp 71.77 -0.49 -0.68% -8.21%
Ionis Pharmaceuticals 34.79 -0.50 -1.42% -5.77%
Intra Cellular Therapies 46.52 0.91 2.00% -21.67%
Neurocrine Biosciences 96.15 1.00 1.05% 3.72%
Nektar Therapeutics 0.81 0.02 2.11% -86.95%
Pfizer 40.37 0.36 0.90% -23.24%
Prothena 48.33 1.36 2.89% 27.75%
Ultragenyx Pharmaceutical 37.64 0.36 0.97% -45.27%
Regeneron Pharmaceuticals 800.28 48.98 6.52% 17.73%
Repligen 167.54 1.29 0.78% -5.23%
Rigel Pharmaceuticals 1.34 -0.01 -0.37% -56.80%
Sarepta Therapeutics 129.88 0.77 0.60% 62.11%
Teva Pharmaceutical Industries Ltd 3,250.00 21.00 0.65% 24.05%
Vertex Pharmaceuticals 304.62 6.75 2.27% 21.03%
Xoma 19.50 0.06 0.31% -30.53%

Indexes Price Day Year
USND 11928 257.97 2.21% -15.95%
US2000 1754 26.68 1.54% -15.49%

Neurocrine Biosciences
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering, developing, and delivering treatments for people with neurological, endocrine and psychiatric disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis, uterine fibroids, and clinical programs in multiple therapeutic areas. The Company's product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has two dosing options (40 milligram (mg) and 80 mg capsules). ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease. ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. ORIAHNN (elagolix, estradiol, and norethindrone acetate; elagolix) is a non-surgical, oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in women.